0001808805-24-000038.txt : 20240430 0001808805-24-000038.hdr.sgml : 20240430 20240429181227 ACCESSION NUMBER: 0001808805-24-000038 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240430 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240430 DATE AS OF CHANGE: 20240429 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Nautilus Biotechnology, Inc. CENTRAL INDEX KEY: 0001808805 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 981541723 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39434 FILM NUMBER: 24893275 BUSINESS ADDRESS: STREET 1: 2701 EASTLAKE AVE EAST CITY: SEATTLE STATE: WA ZIP: 98102 BUSINESS PHONE: 206-333-2001 MAIL ADDRESS: STREET 1: 2701 EASTLAKE AVE EAST CITY: SEATTLE STATE: WA ZIP: 98102 FORMER COMPANY: FORMER CONFORMED NAME: ARYA Sciences Acquisition Corp III DATE OF NAME CHANGE: 20200408 8-K 1 naut-20240430.htm 8-K naut-20240430
0001808805FALSE00018088052024-04-302024-04-30



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 30, 2024
NAUTILUS BIOTECHNOLOGY, INC.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction
of incorporation)
001-39434
(Commission File Number)
98-1541723
(I.R.S. Employer
Identification No.)
2701 Eastlake Avenue East
Seattle, Washington
(Address of principal executive offices)
98102
(Zip code)
(206) 333-2001
(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.0001 per share
NAUT
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company  x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  o


Item 2.02.    Results of Operations and Financial Condition.
On April 30, 2024, Nautilus Biotechnology, Inc. issued a press release reporting its financial results for the quarter ended March 31, 2024. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.
The information furnished in this Current Report under Item 2.02 and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01.    Financial Statements and Exhibits.
(d)    Exhibits
Exhibit
Number
Description
104Cover page Interactive Data File (embedded with the Inline XBRL document)
2

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: April 30, 2024
NAUTILUS BIOTECHNOLOGY, INC.
By:/s/ Sujal Patel
Name:Sujal Patel
Title:Chief Executive Officer

 EX-99 2 exhibit991-q1248xkearnings.htm EX-99 Document
Exhibit 99.1
Nautilus Biotechnology Reports First Quarter 2024 Financial Results
SEATTLE, WA, April 30, 2024 – Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial results for the first quarter ended March 31, 2024.

“We continued to make solid progress against our core development goals in Q1,” said Sujal Patel, CEO of Nautilus. “We remain incredibly focused on increasing the scale, stability, and reproducibility of our consumables, assay, instrument, and software and continue to see meaningful gains along each of those dimensions. We are clear-eyed about what work remains to be done and confident that we have a foundational understanding of what is required to establish a new gold standard for the creation and comprehensive analysis of high-value proteomic data.”
First Quarter 2024 Financial Results
Operating expenses were $21.6 million for the first quarter of 2024, a $3.5 million or 20% increase from $18.1 million for the corresponding prior year period. The increase in operating expenses was driven primarily by an increase in headcount to support ongoing development of our products.
Net loss was $18.7 million for the first quarter of 2024, as compared to a net loss of $15.0 million for the corresponding prior year period.
Cash, cash equivalents, and investments were $247.7 million as of March 31, 2024.
Webcast and Conference Call Information
Nautilus will host a conference call to discuss the first quarter 2024 financial results, business developments and outlook before market open on Wednesday, April 30, 2024 at 5:30 AM Pacific Time / 8:30 AM Eastern Time. Live audio of the webcast will be available on the “Investors” section of the company website at: www.nautilus.bio.
About Nautilus Biotechnology, Inc.
With its corporate headquarters in Seattle, Washington and its research and development headquarters in San Carlos, California, Nautilus is a development stage life sciences company working to create a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus’ mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit www.nautilus.bio
Special Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of federal securities laws. Forward-looking statements in this press release include, but are not limited to, statements regarding Nautilus’ expectations regarding the company’s business operations, financial performance and results of operations; expectations with respect to any revenue timing or projections, expectations with respect to the development required for and the timing of the launch of Nautilus’ product platform and full commercial availability, the functionality and performance of Nautilus’ product platform, its potential impact on providing proteome access, pharmaceutical development and drug discovery, expanding research horizons, and enabling scientific explorations and discovery, and the present and future capabilities and limitations of emerging proteomics technologies. These statements are based on numerous assumptions concerning the development of Nautilus’ products, target markets, and other current and emerging proteomics technologies, and involve substantial risks, uncertainties and other factors that may cause actual results to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that could materially affect the accuracy of Nautilus’ assumptions and its ability to achieve the forward-looking statements set forth in this press release include (without limitation) the following: Nautilus’ product platform is not yet commercially available and remains subject to significant scientific and technical development, which is inherently challenging and difficult to predict, particularly with respect to highly novel and complex products such as those being developed by Nautilus. Even if our development efforts are successful, our product platform will require substantial validation of its functionality and utility in life science research. In the course of Nautilus’ scientific and technical development and associated product validation and commercialization, we may experience material delays as a result of unanticipated events. We cannot provide any guarantee or assurance with respect to the outcome of our development, collaboration, and commercialization initiatives or with respect to their associated timelines. For a more detailed description of additional risks and uncertainties facing Nautilus and its development efforts, investors should refer to the information under the caption “Risk Factors” in our Annual Report on Form 10-K as well as in our Quarterly Report on Form 10-Q to be filed for the quarter ended
1

March 31, 2024 and our other filings with the SEC. The forward-looking statements in this press release are as of the date of this press release. Except as otherwise required by applicable law, Nautilus disclaims any duty to update any forward-looking statements. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.
Disclosure Information

Nautilus uses filings with the Securities and Exchange Commission, its website (www.nautilus.bio), press releases, public conference calls, public webcasts, and its social media accounts as means of disclosing material non-public information and for complying with Regulation FD. Therefore, Nautilus encourages investors, the media, and others interested in Nautilus to review the information it makes public in these locations, as such information could be deemed to be material information.
Media Contact
press@nautilus.bio
Investor Contact
investorrelations@nautilus.bio
2
Nautilus Biotechnology, Inc.
Condensed Consolidated Balance Sheets
As of March 31, 2024 and December 31, 2023 (Unaudited)
(in thousands, except share and per share amounts)March 31, 2024December 31, 2023
Assets
Current assets:
Cash and cash equivalents$25,729 $19,397 
Short-term investments155,637 154,021 
Prepaid expenses and other current assets3,728 3,419 
Total current assets185,094 176,837 
Property and equipment, net4,525 4,267 
Operating lease right-of-use assets31,559 32,634 
Long-term investments66,292 90,647 
Other long-term assets1,180 1,180 
Total assets$288,650 $305,565 
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable$1,860 $1,639 
Accrued expenses and other liabilities3,677 3,945 
Current portion of operating lease liabilities3,675 3,538 
Total current liabilities9,212 9,122 
Operating lease liabilities, net of current portion29,946 31,090 
Total liabilities39,158 40,212 
Stockholders' equity:
Preferred stock— — 
Common stock13 13 
Additional paid-in capital471,193 467,834 
Accumulated other comprehensive income (loss)(745)(255)
Accumulated deficit(220,969)(202,239)
Total stockholders’ equity249,492 265,353 
Total liabilities and stockholders' equity$288,650 $305,565 

3
Nautilus Biotechnology, Inc.
Condensed Consolidated Statements of Operations
Three Months Ended March 31, 2024 and 2023 (Unaudited)
Three Months Ended March 31,
(in thousands, except share and per share data)20242023
Operating expenses
Research and development$12,930 $10,877 
General and administrative8,677 7,183 
Total operating expenses21,607 18,060 
Other income (expense)
Interest income2,877 3,098 
Other expense— (3)
Total other income$2,877 $3,095 
Net loss$(18,730)$(14,965)
Net loss per share attributable to common stockholders, basic and diluted$(0.15)$(0.12)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted125,135,451 124,590,351 

4
Nautilus Biotechnology, Inc.
Condensed Consolidated Statements of Cash Flows
Three Months Ended March 31, 2024 and 2023 (Unaudited)

Three Months Ended March 31,
(in thousands)20242023
Cash flows from operating activities
Net loss$(18,730)$(14,965)
Adjustments to reconcile net loss to net cash used in operating activities
Stock-based compensation expense3,114 2,860 
Amortization of operating lease right-of-use assets1,075 786 
Depreciation516 385 
Amortization (accretion) of premium (discount) on securities, net(751)(669)
Changes in operating assets and liabilities:
Prepaid expenses and other assets(309)(513)
Accounts payable94 53 
Accrued expenses and other liabilities(268)65 
Operating lease liabilities(1,007)(526)
Net cash used in operating activities(16,266)(12,524)
Cash flows from investing activities
Proceeds from maturities of securities23,000 14,249 
Purchases of securities— (27,052)
Purchases of property and equipment(647)(692)
Net cash provided by (used in) investing activities22,353 (13,495)
Cash flows from financing activities
Proceeds from exercise of stock options245 1 
Net cash provided by financing activities245 1 
Net increase (decrease) in cash, cash equivalents and restricted cash6,332 (26,018)
Cash, cash equivalents and restricted cash at beginning of period20,399 115,477 
Cash, cash equivalents and restricted cash at end of period$26,731 $89,459 

5
 EX-101.SCH 3 naut-20240430.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 naut-20240430_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Security Exchange Name Security Exchange Name Title of 12(b) Security Title of 12(b) Security Written Communications Written Communications Local Phone Number Local Phone Number Trading Symbol Trading Symbol Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, State or Province Entity Address, State or Province Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Document Period End Date Document Period End Date Cover [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Pre-commencement Tender Offer Pre-commencement Tender Offer Soliciting Material Soliciting Material City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Document Type Document Type Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Entity Ex Transition Period Entity Ex Transition Period Entity File Number Entity File Number Entity Address, City or Town Entity Address, City or Town Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Registrant Name Entity Registrant Name EX-101.PRE 5 naut-20240430_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Cover
Apr. 30, 2024
Cover [Abstract]  
Document Type 8-K
Document Period End Date Apr. 30, 2024
Entity Registrant Name NAUTILUS BIOTECHNOLOGY, INC.
Entity Incorporation, State or Country Code DE
Entity File Number 001-39434
Entity Tax Identification Number 98-1541723
Entity Address, Address Line One 2701 Eastlake Avenue East
Entity Address, City or Town Seattle
Entity Address, State or Province WA
Entity Address, Postal Zip Code 98102
City Area Code 206
Local Phone Number 333-2001
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol NAUT
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
Entity Central Index Key 0001808805
Amendment Flag false
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 1 23 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Cover Sheet http://www.nautilus.bio/role/Cover Cover Cover 1 false false All Reports Book All Reports naut-20240430.htm naut-20240430.xsd naut-20240430_lab.xml naut-20240430_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "naut-20240430.htm": { "nsprefix": "naut", "nsuri": "http://www.nautilus.bio/20240430", "dts": { "inline": { "local": [ "naut-20240430.htm" ] }, "schema": { "local": [ "naut-20240430.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "naut-20240430_lab.xml" ] }, "presentationLink": { "local": [ "naut-20240430_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 24, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://www.nautilus.bio/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "naut-20240430.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "naut-20240430.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.nautilus.bio/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.nautilus.bio/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.nautilus.bio/role/Cover" ], "lang": { "en-us": { "role": { "verboseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.nautilus.bio/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.nautilus.bio/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.nautilus.bio/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.nautilus.bio/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.nautilus.bio/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.nautilus.bio/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.nautilus.bio/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://www.nautilus.bio/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Ex Transition Period", "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.nautilus.bio/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.nautilus.bio/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.nautilus.bio/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.nautilus.bio/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.nautilus.bio/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.nautilus.bio/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Issuer Tender Offer", "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.nautilus.bio/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Tender Offer", "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.nautilus.bio/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.nautilus.bio/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.nautilus.bio/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Soliciting Material", "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.nautilus.bio/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.nautilus.bio/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Written Communications", "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001808805-24-000038-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001808805-24-000038-xbrl.zip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end XML 17 naut-20240430_htm.xml IDEA: XBRL DOCUMENT 0001808805 2024-04-30 2024-04-30 0001808805 false 8-K 2024-04-30 NAUTILUS BIOTECHNOLOGY, INC. DE 001-39434 98-1541723 2701 Eastlake Avenue East Seattle WA 98102 206 333-2001 false false false false Common Stock, par value $0.0001 per share NAUT NASDAQ true false